Neuphoria Therapeutics (NEUP) Non Operating Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Non Operating Income of $671793.0 for Q1 2026, up 184.37% year-over-year from $236236.6 in Q1 2025, and down 88.59% quarter-over-quarter from $5.9 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Non Operating Income (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Non Operating Income for 4 consecutive years, with $671793.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 184.37% year-over-year to $671793.0; the TTM figure through Mar 2026 stood at -$1.0 million (down 116.37% YoY), while the FY2025 annual figure was $291093.0, down 87.41% from the prior year.
- Non Operating Income slipped to $671793.0 in Q1 2026 per NEUP's latest filing, from $5.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at $5.9 million in Q4 2025 and bottomed at -$4.3 million in Q3 2025.
- Historically, Non Operating Income has averaged $443389.0 across 4 years, with a median of -$36356.0 in 2023.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 6717.58% — and 2025, when it sank 263.02%.
- Neuphoria Therapeutics' Non Operating Income stood at -$36356.0 in 2023, then jumped by 4973.39% to $1.8 million in 2024, then jumped by 232.44% to $5.9 million in 2025, then plunged by 88.59% to $671793.0 in 2026.
- Business Quant data shows NEUP's Non Operating Income at $671793.0 in Q1 2026, $5.9 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | 671,793.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 671,793.00 |
| Dec 31, 2025 | 5.89 Mn |
| Sep 30, 2025 | -4.29 Mn |
| Jun 30, 2025 | -3.32 Mn |
| Mar 31, 2025 | -796,218.00 |
| Dec 31, 2024 | 1.77 Mn |
| Sep 30, 2024 | 2.63 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2024 | -367,734.00 |
| Dec 31, 2023 | -36,356.00 |
| Sep 30, 2023 | -39,754.00 |